PedAM
Pediatric Disease Annotations & Medicines
| Disease | arteriosclerosis |
| Phenotype | C0022658|renal disease |
| Sentences | 17 |
| PubMedID- 25884772 | Subclinical atherosclerosis in patients with chronic non-dialytic renal disease. |
| PubMedID- 22851960 | Chronic inflammation and coronary atherosclerosis in patients with end-stage renal disease. |
| PubMedID- 24524553 | In addition to accelerated atherosclerosis, patients with end-stage renal disease are subject to diffuse medial calcification in the blood vessels; this is associated with increased cardiovascular mortality. |
| PubMedID- 22188103 | Determinants of premature atherosclerosis in children with end-stage renal disease. |
| PubMedID- 21996186 | Conclusion: in end-stage renal disease patients with severe atherosclerosis in the aortoiliac region, vascular reconstruction allows kidney transplantation. |
| PubMedID- 26435827 | atherosclerosis in renal disease is associated with markers of impaired fibrinolysis. |
| PubMedID- 20955275 | Further studies are needed to clarify whether an increased plasma fgf-23 level is a marker or a potential mechanism for atherosclerosis in patients with end-stage renal disease. |
| PubMedID- 23653846 | Several studies have been done to illustrate the mechanism and cause of accelerated atherosclerosis in patients with end stage renal disease and to suggest some possible mechanisms involved in this process including endothelial dysfunction, oxidative stress, immune system disorder, high lipoprotein (a) level, hemocysteinemia and elevated tumor necrosing factor α (tnfα) and interlukin-6 (il-6) (7-9). |
| PubMedID- 24561478 | Traditional risk factors, such as age, diabetes, and hypertension, as well as non-traditional risk factors, such as uremic toxins, anemia, and ca/p abnormalities, play central roles in the pathogenesis of atherosclerosis in patients with renal disease [5,6]. |
| PubMedID- 24049267 | Further studies are needed with large population numbers to establish the positive predictive value and reliability of sci as a marker of atherosclerosis in patients with end-stage renal disease. |
| PubMedID- 20861651 | Conclusion: the plasma level of opg could serve as a surrogate marker of progression of atherosclerosis and calcification in patients with end-stage renal disease. |
| PubMedID- 24530961 | Additionally, chronic acidosis in end stage chronic renal disease is associated with accelerated atherosclerosis and cardiovascular morbidity and mortality [12]. |
| PubMedID- 24137221 | Microinflammation is a major cause of atherosclerosis in patients with end-stage renal disease (esrd). |
| PubMedID- 22388608 | Introduction: end-stage renal disease has been associated with premature atherosclerosis of the cerebral circulation. |
| PubMedID- 19931862 | Objectives: we propose that impaired regression of atherosclerosis in renal disease represents a novel risk factor for the heightened morbidity and mortality and resistance to treatment observed in patients with ckd. |
| PubMedID- 26246038 | Purpose: aside from traditional factors (e.g., diabetes, age, and hypertension), some hematological parameters, such as neutrophil-to-lymphocyte ratio (nlr), red blood cell distribution width (rdw), and mean platelet volume (mpv), have increasingly been reported as measures of systemic inflammation and atherosclerosis in patients with end-stage renal disease (esrd). |
| PubMedID- 21288312 | Malnutrition-inflammation-atherosclerosis syndrome in patients with end-stage renal disease. |
Page: 1